Detalhe da pesquisa
1.
Second-line treatment for acute graft-versus-host disease with mesenchymal stromal cells: A decision model.
Eur J Haematol
; 2018 Aug 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30084111
2.
Safety of allogeneic bone marrow derived mesenchymal stromal cell therapy in renal transplant recipients: the neptune study.
J Transl Med
; 13: 344, 2015 Nov 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-26537851
3.
Autologous bone marrow derived mesenchymal stromal cell therapy in combination with everolimus to preserve renal structure and function in renal transplant recipients.
J Transl Med
; 12: 331, 2014 Dec 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-25491391
4.
Differential immunomodulatory effects of fetal versus maternal multipotent stromal cells.
Hum Immunol
; 70(1): 16-23, 2009 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-19010366
5.
Impaired effector memory T-cell regulation facilitates graft versus host disease in CCR7-deficient bone marrow transplant chimeras.
Transplantation
; 88(5): 631-9, 2009 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-19741459
6.
Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study.
Blood
; 101(6): 2144-51, 2003 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-12456509